Stonepine Capital Management, LLC Dia Medica Therapeutics Inc. Transaction History

Stonepine Capital Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.86 - $2.62 $38,875 - $54,760	-20,901 Reduced 1.75%	1,176,344 $2.38 Million
Q1 2022 May 16, 2022	BUY	$2.29 - $3.88 $5,896 - $9,991	2,575 Added 0.22%	1,197,245 $2.99 Million
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $3.53 Million - $4.78 Million	1,028,895 Added 620.66%	1,194,670 $4.46 Million
Q3 2021 Nov 12, 2021	SELL	$3.1 - $4.32 $787,917 - $1.1 Million	-254,167 Reduced 60.52%	165,775 $665,000
Q2 2021 Aug 16, 2021	SELL	$4.45 - $9.91 $2.69 Million - $5.98 Million	-603,467 Reduced 58.97%	419,942 $1.87 Million
Q1 2021 May 14, 2021	BUY	$7.76 - $10.43 $569,653 - $765,655	73,409 Added 7.73%	1,023,409 $9.36 Million
Q4 2020 Feb 12, 2021	SELL	$4.13 - $10.14 $811,421 - $1.99 Million	-196,470 Reduced 17.14%	950,000 $9.63 Million
Q3 2020 Nov 13, 2020	BUY	$3.91 - $7.15 $1.87 Million - $3.42 Million	478,040 Added 71.52%	1,146,470 $4.86 Million
Q2 2020 Aug 13, 2020	SELL	$2.6 - $7.32 $407,854 - $1.15 Million	-156,867 Reduced 19.01%	668,430 $4.63 Million
Q1 2020 May 14, 2020	BUY	$2.25 - $5.64 $1.86 Million - $4.65 Million	825,297 New	825,297 $2.31 Million
Q4 2019 Feb 13, 2020	SELL	$1.8 - $5.04 $24,669 - $69,073	-13,705 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$2.07 - $4.88 $28,369 - $66,880	13,705 New	13,705 $28,000
Q2 2019 Aug 13, 2019	SELL	$2.7 - $4.96 $675,000 - $1.24 Million	-250,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$3.1 - $4.54 $775,000 - $1.14 Million	250,000 New	250,000 $1.14 Million

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $144M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.